Table 2 Clinical characteristics of patients.
| Characteristics | Group 1 | Group 2 | Group 3 | Group 4 |
|---|---|---|---|---|
| Number | 20 | 4 | 5 | 5 |
| Sex | ||||
| Male | 15 (75%) | 3 (75%) | 3 (60%) | 3 (60%) |
| Female | 5 (25%) | 1 (25%) | 2 (40%) | 2 (40%) |
| Age (y) | ||||
| Mean | 65 | 62 | 72 | 54.4.0 |
| Range | 8–86 | 48–92 | 58–73 | 7–84 |
| Extent of skin lesion | ||||
| Solitary | 3 (15%) | 3 (75%) | 2 (40%) | 2 (40%) |
| Generalised | 17 (85%) | 1 (25%) | 3 (60%) | 3 (60%) |
| Involved extracutaneous sites | ||||
| No extracutaneous involvement | 0 (0%) | 0 (100%) | 1 (20%) | 5 (100%) |
| Lymph nodes | 13 (65%) | 1 (25%) | 2 (40%) | 0 (0%) |
| Visceral organs | 0 (0%) | 0 (0%) | 1 (20%) | 0 (0%) |
| Peripheral blood | 4 (20%) | 1 (25%) | 0 (0%) | 0 (0%) |
| Bone marrow | 13 (65%) | 2 (50%) | 1 (20%) | 0 (0%) |
| Palate | 3 (15%) | 0 (0%) | 2 (40%) | 0 (0%) |
| Other neoplasia | 2 (10%)* | 0 (0%) | 0 (0%) | 0 (0%) |
| Therapy | 0 (0%) | |||
| Phototherapy | 0 (0%) | 0 (0%) | 0 (0%) | 1 (20%) |
| Multiagent chemotherapy | 15 (75%) | 3 (75%) | 4 (80%) | 1 (20%) |
| Radiotherapy | 2 (10%) | 1 (25%) | 1 (20%) | |
| Bone marrow transplantation | 2 (10%) | 1 (25%) | 0 (0%) | 0 (0%) |
| Survival, months | ||||
| Median | 12 | 11 | 7 | +62 |
| Range | 3–55 | 3–60 | 2–72 | |
| Current status | ||||
| No evidence of disease | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Alive with disease | 0 (0%) | 0 (0%) | 1 (20%) | 5 (100%) |
| Died of lymphoma | 19 (95%) | 4 (100%) | 4 (80%) | 0 (0%) |
| Died of other cause | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Group 1, haematodermic neoplasm; group 2, cutaneous infiltrates of acute myeloid leukaemia; group 3, extranodal NK/T‐cell lymphoma; group 4, “classical CTCL” with expression of CD56.
*One patient developed in addition a chronic myeloid leukaemia, and another patient a myelodysplastic syndrome.